PRLD News and Press, Prelude Therapeutics Incorporated From 09/09/22

Prelude Therapeutics ( NASDAQ: PRLD ) inched lower on Friday after Morgan Stanley downgraded the cancer-focused biotech to Equal Weight from Overweight as the company plans to disclose key steps forward for its PRMT5 program, including the solid tumor candidate PRT811 in H2 ...

WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City. ...

Prelude Therapeutics press release ( NASDAQ: PRLD ): Q2 GAAP EPS of -$0.58. Cash and cash equivalents and marketable securities of $246.3 million as of June 30, 2022, expected to fund operations into the second half of 2024 For further details see: Prelude Therap...

Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 are on track for the...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Prelude Therapeutics press release (NASDAQ:PRLD): Q1 GAAP EPS of -$0.63 beats by $0.02. Cash and cash equivalents of $266.2M For further details see: Prelude Therapeutics GAAP EPS of -$0.63 beats by $0.02

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTO...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Prelude Therapeutics press release (NASDAQ:PRLD): FY GAAP EPS of -$2.43 misses by $0.01. Cash and cash equivalents and marketable securities as of December 31, 2021 were $291.2M. For further details see: Prelude Therapeutics GAAP EPS of -$2.43 misses by $0.01